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Hepatitis E in patients with hepatic disorders and HIV-infected patients in Croatia – is one 
diagnostic method enough for hepatitis E diagnosis? 
 
Oktavija Dakovic Rode, Lorena Jemersic, Dragan Brnic, Nenad Pandak, Radojka Mikulic, Josip 
Begovac, Adriana Vince 
 
Abstract:   
 
We assessed hepatitis E virus (HEV) seroprevalence in patients with hepatic disorders as well as 
in HIV-infected patients and emphasised the issue of possible non-specific anti-HEV 
seroresponse and need for combining diagnostic methods for hepatitis E diagnosis.  
Over a two-year period, from March 2011 to February 2013, we determined anti-HEV IgM and 
IgG by enzyme-immunoassays (EIA) (Mikrogen, Germany) in 504 hepatitis patients negative for 
acute viral hepatitis A-C. Furthermore, 88 samples from randomly selected consecutive HIV-
infected patients were also analysed. All EIA reactive samples were additionally tested by line-
immunoblot assays (LIA; Mikrogen, Germany). HEV nested RT-PCR was carried out in 14 anti-
HEV IgM LIA positive patients. 
Anti-HEV IgM or IgG were detected in 16.9% patients by EIA and confirmed by LIA in 10.7% 
(95% CI 8.3-13.7%) of hepatitis patients. HEV RNA was detected in 5 patients. The agreement 
between EIA and LIA assessed by Cohen’s Kappa was for IgM 0.47 (95% CI 0.55-0.75) and for 
IgG 0.83 (95% CI 0.78-0.93). Anti-HEV IgM and IgG seroprevalence in HIV-infected patients 
was 1.1%, respectively. 
Our findings show a rather high HEV seroprevalence in patients with elevated liver enzymes in 
comparison to HIV-infected patients. Discordant findings by different methods stress the need to 
combine complementary methods and use a two-tier approach with prudent interpretation of 
reactive serological results for hepatitis E diagnosis.  
 
 
Key words: hepatitis E, HEV seroprevalence, serodiagnosis, enzyme-immunoassay, line-
immunoassay, two-tier testing, PCR, Croatia 
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Introduction 
 
Hepatitis E infection is an emerging disease displaying hyperendemic outbreaks in 
developing countries and yet seems to be underestimated in industrialised regions. The cause of 
hepatitis E is a small non-enveloped RNA virus with 4 genotypes recognized in humans [1]. 
Hepatitis E virus (HEV) genome contains short non-coding regions and three discontinuous and 
partially overlapping open reading frames (ORF) for viral non-structural proteins (ORF1), viral 
capsid protein (ORF2) and proteins with still unclear functions from ORF3 [2, 3]. In developing 
regions outbreaks are generally caused by human specific genotypes 1 and 2 which are 
recognized as travel-associated HEV infections in developed countries. Genotypes 3 and 4 are 
considered to be causes of endemic infections with zoonotic potential since they were isolated 
from humans but also from different mammalian species and marine animals [4-10]. HEV is 
acquired through the fecal-oral route, although sources of HEV frequently stay unrecognized [4-
12]. Hepatitis E clinical presentation in healthy individuals is usually mild and self-limiting and 
patients may even not seek medical attention [4, 5]. In contrary, in severely immunosuppressed 
patients chronic HEV infection could be a cause of persistent alanin aminotransferase (ALT) 
elevation. So, HEV persistence may be a potential risk of disease progression also in HIV-
infected patients [13-17]. HEV infection needs to be considered as a possible cause of 
unexplained increase in liver enzymes when common viral causes of hepatitis are excluded.  
The diagnosis of HEV infection is based on serological determination of anti-HEV IgM 
and IgG antibodies and/or nucleic acid-based testing [5, 18-20]. Viremia is limited to the acute 
phase of illness, and both anti-HEV IgM and IgG are generally detectable at the onset of disease. 
Anti-HEV IgM decline rapidly and 3-6 months after the occurrence of the first symptoms are 
undetectable while a rise in IgG antibody titre is observed [21]. Acute hepatitis E is defined when 
anti-HEV IgM and IgG in serum or HEV RNA is documented. The finding of anti-HEV IgM 
when IgG and HEV RNA remain undetectable could not be considered as an acute hepatitis E 
infection. Serological HEV diagnostic is not standardized. Diagnostic performances and results 
differ in specificity and sensitivity of used commercially available assays. Serological findings 
depend on the principle of enzyme-immunoassays (EIA; indirect or µ-capture method) and the 
used antigen selections and conformations [5, 14, 18-24]. Although HEV is antigenically 
consistent and only one serotype has been identified, recombinant antigens used for antibody 
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testing are not optimized. New generation assays based on HEV-ORF2 genotype 1 and 3 
(Wantai/Fortress, Mikrogen) represent a significant step towards establishing serological 
standards [20-23].  
Hepatitis E is a notifiable disease in Croatia since 1994. Until 2012 only a few travel 
associated HEV cases per year were registered [25, 26]. Even so, HEV has been detected in 
domestic swine and wild boars [8, 27] resulting in a possibility of viral spread to humans [28]. 
Therefore, accurate and quick diagnosis is needed to distinguish HEV infection from other causes 
of acute viral hepatitis. The aim of this study was to assess HEV seroprevalence in patients with 
hepatic disorders as well as HIV-infected patients and to evaluate the serological diagnosis of 
hepatitis E using EIA followed by LIA and RT-PCR.  
  
Patients and methods 
 
Over a 2-year period, from March 2011 until February 2013, sera from 504 patients (age 
range 16 to 81 years) with elevated liver enzymes (ALT and AST >2xULN) were serologically 
tested at the University Hospital for Infectious Diseases in Zagreb for viral hepatitis E. 
Furthermore, 88 sera samples from randomly retrospectively selected consecutive HIV-infected 
patients (age range 20 to 80 years) were also tested for the presence of anti-HEV IgM and IgG. 
Moreover, CD4 cell count was available for 85 of the HIV-infected patients included in the study 
with a median of 279 cells/mm3 (interquartile range, 129-488 cells/mm3). The number of the 
latter samples represents approximately 10% of all registered HIV-infected patients in Croatia.  
Acute viral hepatitis A-C were excluded according to specific markers: anti-HAV IgM, 
anti-HAV total (DiaSorin, Italy), HbsAg (Murex/DiaSorin, Italy), anti-HBs, anti-HBc, anti-HBc 
IgM, anti-Hbe, HbeAg (DiaSorin, Italy), anti-HCV (HCV Ag/Ab Biorad, France). EBV and 
CMV infections were serologicaly defined with assays for anti-CMV IgM and IgG (DiaSorin, 
Italy), anti-VCA EBV IgM and IgG respectively, anti-EA EBV IgG and anti-EBNA IgG 
(DiaSorin, Italy). The testing included detection of anti-HEV IgM and IgG by EIA with 
recombinant HEV ORF2 (genotype 1 and 3) antigens (recomWell HEV IgG, IgM; Mikrogen 
GmbH, Germany). All samples with primarily positive or borderline EIA findings were 
additionally tested by LIA (recomLine HEV IgG/IgM, Mikrogen GmbH, Germany). LIA was 
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used as a supplemented method and the standard for result interpretation. All procedures were 
managed according to the manufacturer’s instructions.  
Positive or borderline anti-HEV EIA results were defined according to a follow-up 
serological testing by LIA. Only LIA positive results were assessed as positive anti-HEV 
antibodies. LIA confirmed anti-HEV IgM and IgG findings in sera were considered as indicators 
of an acute hepatitis E. Anti-HEV IgM positive and IgG negative findings were interpreted as 
indicators of a possible recent HEV infection. Positive anti-HEV IgG accompanied with negative 
IgM was considered as an indicator of a past infection.  
For confirmation of acute and recent HEV infection a nested RT-PCR was carried out in 
14 patients by a protocol described by van der Poel [7]. HEV RT-PCR was conducted on sera 
with positive anti-HEV IgM. A fragment of 287 bp within the metal-transferase gene region of 
ORF1 was the amplification target. RNA was isolated by QIAamp® Viral RNA Kit (Qiagen, 
Germany), according to the manufacturer’s instructions. The reverse transcription was carried out 
using GoScript Reverse Transcription System for RT-PCR (Promega, USA) in a Gene Amp PCR 
System 9700 machine (Applied Biosystems, USA). Thirty-five PCR cycles were conducted by 
the use of 2 pairs of primers (nested PCR). Electrophoresis was done in a 1.5% agarose gel. All 
samples with a band of 287 bp were considered as HEV positive. 
The agreement between EIA and LIA for IgM and IgG anti-HEV assays was quantified 
with the Cohen’s Kappa coefficient. Statistical analysis was performed using the Statistica 8.0 
(StatSoft). 
 
 
Results  
 
Anti-HEV reactive antibodies determined by EIA were found in 85 of the 504 (16.9%) 
patients with hepatic disorders. Of the 85 anti-HEV EIA positive patients 42 (49.4%) were males, 
with a median of 48 years of age. Anti-HEV IgM and IgG were reactive by EIA in 46 (54.1%) 
and 51 (60.0%) of the 85 patients, respectively (Fig 1a). Anti-HEV antibodies were confirmed by 
LIA in 54 of the 85 (63.5%) EIA-reactive patients. Anti-HEV IgM and IgG were positive by LIA 
in 16 of 46 (34.8%) and 44 of 51 (86.3%) EIA-reactive patients, respectively. Unconfirmed EIA 
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reactive anti-HEV IgM or IgG antibodies had 31 (6.2%) patients. Anti-HEV antibodies were 
confirmed by LIA in 10.7% of all hepatitis HIV-negative patients.  
Even though 11 (12.5%) HIV-infected patients displayed EIA positive anti-HEV IgM, 
only in one patient (1.1%) the positive EIA result was positive also by LIA. However, this patient 
had no clinical signs or elevated liver enzymes, so a possible false positive LIA finding could not 
be excluded. Of the 88 HIV-infected patients, one (1.1%) had confirmed anti-HEV IgG 
antibodies as a sign of past infection (Fig 1b).  
Different serological IgM and IgG profiles were found by EIA in comparison to LIA 
(Table 1). Borderline LIA findings, 5 for IgM and 2 for IgG, were considered as negative. In 12 
patients with combined EIA reactive IgM and IgG, anti-HEV were confirmed by LIA in 6 for 
IgM and IgG, 4 for only IgG and 1 for IgM while one patient had IgM LIA borderline and IgG 
negative. Anti-HEV antibodies stayed unconfirmed for 30 of 46 (65.2%) IgM and 7 of 51 
(13.7%) IgG EIA reactive results. The agreement between EIA and LIA assessed by the Cohen’s 
Kappa coefficient was for IgM 0.47 (95% CI 0.55-0.75) and for IgG 0.83 (95% CI 0.78-0.93). 
HEV RT-PCR was conducted in patients with positive anti-HEV IgM and HEV RNA was 
found in 5 of 14 (35.7%) tested patients.  
To determine the influence of other hepatotropic viruses, except for viral hepatitis A-C 
patients were also tested for EBV and CMV. Among patients with anti-HEV antibodies, 42 
(49.4%) had serological signs of past HAV, HBV or HCV infection. Anti-HAV was most 
commonly detected (Table 2). 
From 16 patients with positive and 5 with borderline LIA anti-HEV IgM, hepatitis was 
caused by CMV in 4 (19.0%) and EBV in 1 (4.8%). One patient with EIA reactive anti-HEV IgM 
that was not confirmed by LIA had an acute EBV infection. Among 8 HIV-infected patients with 
EIA positive anti-HEV IgM acute CMV infection was found in 3 (37.5%), EBV in 1 (12.5%), 
and 1 (12.5%) HIV-infected patient had sifilis. 
Specific antibodies against different HEV antigens are displayed by LIA of which the 
most represented were anti-HEV IgM for O2N antigen (47.8%) and IgG for O2C antigen (86.3%) 
(Fig 2). The reactivity to the HEV O3 antigen was high for both antibody classes, while low 
against O2M antigen. The differentiation between HEV genotypes 1 and 3 according to the bands 
reactivity might be only assumed but was not reliable. Further validation is needed.   
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a) 
b)
Patients with elevated liver enzymes 
(AST/ALT >2xULN)
504
Anti-HEV IgM/IgG EIA reactive*
85 (16.9%)
Anti-HEV IgM/IgG LIA positive 
54 (10.7%)
Anti-HEV IgM/IgG EIA negative
419 (83.1%) 
Anti-HEV LIA
IgM positive / IgG negative  10 (2.0%)  1 HCV RNA positive
IgM positive / IgG positive     6  (1.2%)  4 HCV RNA positive
IgM negative / IgG positive  38 (7.5%)
Anti-HEV IgM/IgG LIA negative
31(6.2%) 
HIV-infected patients
88
Anti-HEV IgM/IgG EIA reactive*
11 (12.5%)
Anti-HEV IgM/IgG LIA positive
2 (2.3%)
Anti-HEV IgM/IgG EIA negative
77 (87.5%) 
Anti-HEV LIA
IgM positive / IgG negative  1 (1.1%)
IgM negative / IgG positive 1 (1.1%)
Anti-HEV IgM/IgG LIA negative
9 (10.2%) 
 
 
Fig. 1 Anti-HEV IgM and IgG antibodies in patients with elevated liver enzymes (AST/ALT >2x 
ULN) and excluded acute viral hepatitis A-C (a) and in HIV-infected patients (b) (EIA, enzyme 
immunoassay; LIA, line-immunoassay; *EIA reactive, positive and borderline results included) 
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Table 1 Anti-HEV IgM and IgG enzyme (EIA) and line-immunoassay (LIA) discordant results 
in hepatitis and HIV-infected patients 
 
Anti-HEV IgM 
EIA* positive EIA borderline Total IgM (%) 
Hepatitis 
patients  
HIV- patients 
Hepatitis 
patients 
HIV- 
patients 
Hepatitis 
patients 
HIV- patients 
LIA** positive 16 1 - - 16 (3.2%) 1 (1.1%) 
LIA borderline 4 1 1 - 5 (1.0%) 1 (1.1%) 
LIA negative 14 6 11 3 483 (95.8%)# 86 (97.7%) 
Total IgM (%) 34 (6.7%) 8 (9.1%) 12 (2.4%) 3 (3.4%) 504 88 
Anti-HEV IgG 
EIA positive EIA borderline Total IgG (%) 
Hepatitis 
patients 
HIV- patients 
Hepatitis 
patients 
HIV- 
patients 
Hepatitis 
patients 
HIV- patients 
LIA positive 38 1 6 - 44 (8.7%) 1 (1.1%) 
LIA borderline 2 1 - 1 2 (0.4%) 2 (2.3%) 
LIA negative 3 - 2 - 458 (90.9%)# 85 (96.6%) 
Total IgG (%) 43 (8.5%) 2 (2.3%) 8 (1.6%) 1 (1.1%) 504 88 
 
*EIA, enzyme immunoassay; **LIA, line-immunoassay; # negative EIA serum was not determined by LIA 
 
 
Table 2 Results in 42 patients with anti-HEV antibodies and serological evidence of past HAV, 
HBV and HCV infection  
 
HAV / HBV / HCV  
Past infection 
N = 42 
Anti-HEV  
LIA IgG 
positive  
LIA IgM 
positive 
LIA IgM+IgG 
positive 
LIA IgM 
borderline 
LIA IgM+IgG negative 
EIA IgM+IgG positive  
HAV 8 2 1 - 9 
HAV / HBV 12 - - 1 - 
HAV / HCV 2 - - - - 
HBV 1 - 2 - 2 
HCV - 1 - - 1 
Total  
% 
23 
54.8% 
3  
7.1% 
3  
7.1% 
1  
2.4% 
12 
28.6% 
 
*LIA, line-immunoassay; EIA, enzyme immunoassay 
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Fig 2. Specific anti-HEV IgM and IgG reactivity in line-immunoassays in serum samples: 
46 for IgM, 51 for IgG (O2N, N-terminal part of ORF2 protein (HEV capsid-protein); O2C, C-
terminal part of ORF2 protein (HEV capsid-protein); O2M, middle part of ORF2 protein (HEV 
capsid-protein); O3, ORF3 protein of HEV; Gt 1, genotype 1; Gt 3 genotype 3) 
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Discussion 
 
Even though Croatia is considered as a country of low HEV incidence with sporadic, 
mostly imported HEV cases [25], the average seroprevalence in patients with non-specific 
elevation of liver enzymes and negative for acute viral hepatitis A-C assessed by EIA followed 
by LIA was 10.7%. HEV seroprevalence gained by EIA only was even higher (16.9%). The HEV 
IgG seroprevalence in HIV-infected patients was lower (1.1%) than in patients with hepatic 
disorders, and might presume the seroprevalence of the adult population in general while HIV-
infected patients according to literature are not at increased risk of acquiring HEV infection [5]. 
Our results show discrepancies related to the used methods and reinforce previous reports on 
difficulties in HEV diagnostic. The strength of agreement between EIA and LIA (Mikrogen) for 
anti-HEV IgG was very good but only moderate for IgM.  
The data on HEV seroprevalence gained by different testing approaches are demanding 
for analysis although in general our results may be comparable with others [10, 13, 20, 22, 29-
33]. There is a high probability that our patients were HEV infected in Croatia since there is no 
recognition of their recent travel to endemic regions and all HEV RNA determined were 
genotype 3 that was documented in swine although a direct connection of viral transmission 
cannot be defined. Therefore the sources of infection remain unrecognized [8, 27]. According to 
EIA anti-HEV IgM even 46 patients could be considered as acute HEV cases but in only 8 of 
them recent HEV infection was confirmed by RT-PCR or the rising IgG titre in a convalescent 
serum. All patients with positive HEV RNA showed a high anti-HEV IgM titre and had 
detectable IgG when they requested medical attention. Only one HEV RNA positive patient had 
anti-HEV IgM without IgG, however the patient seroconverted to IgG very soon. The findings 
support previous reports that only anti-HEV IgM detected in one serum sample is not sufficient 
for establishing HEV diagnosis [5, 20, 24, 29, 34-37]. Reactive anti-HEV IgM may be the result 
of polyclonal B cell activation by EBV or other infections which can induce B cells [24, 34-37]. 
False positive IgM anti-HEV due to acute EBV, CMV and syphilis were documented also in our 
patients. Overdiagnosis of acute hepatitis E due to possible false positive results should not be 
neglected and needs to be recognized and reduced. One possible solution may be the use of a 
two-tier approach with combining anti-HEV IgM and IgG screening by EIA with additional 
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testing by line-immunoassay (LIA). Detection of HEV RNA is always recommended especially 
in recent illness [18].  
The limitations of the study need to be noted. We used LIA and EIA assays based on the 
same antigens from the same manufacturer (Mikrogen). However, similar two-tier testing 
approaches are used for borreliae and HCV to show specific reactions against separate antigens 
and to exclude unspecific EIA reactions. According to published data for patients with positive 
HEV RNA the specificity and sensitivity of newer serological tests show very good performances 
[5, 20-23], but in routine clinical practice patients with different simultaneous diagnoses may 
gain unspecific ambiguous anti-HEV results, so the seroprevalence rates may differ significantly 
according to used diagnostic protocols. Low positive predictive values, even for high sensitive 
EIA due to low prevalence, imposes the need to check all positive and borderline results [20]. 
This supports the importance of combining at least two assays to assess the result. A two-step 
testing approach with anti-HEV IgM and IgG EIA and LIA, which has a positive impact 
regarding to the specificity, could be recommended. A further solution could also be combining 
two EIAs with high sensitivity and specificity [14, 21, 22].  
LIA was criticized for its low sensitivity [23], even though it is not intended for screening 
purposes (high cost, labour complexity) but for confirmation. According to our clinical practice 
patients with unconfirmed LIA anti-HEV IgM were unlikely to be HEV infected; some of them 
had other hepatitis infections that emphasizes the importance of differential diagnosis. In our 
study, positive anti-HEV antibodies were found in 49.4% of patients with a past HAV, HBV or 
HCV infection and the clinical impact of HEV in these patients is yet to be defined since co-
infection with HEV could pose as a severe health risk among persons with pre-existing chronic 
liver disease [13, 14, 17, 32]. 
From our limited experience, immunocompetent patients with acute hepatitis E when 
seeking medical attention mostly have detectable antibodies by EIA and LIA. Viremia seems to 
be documented as long as IgM exceeds the IgG titre. Acute HEV infection with only anti-HEV 
IgM findings and without HEV RNA seems to be rarely possible. When HEV RNA decreases to 
undetectable levels anti-HEV IgM decline as well, while anti-HEV IgG titres increase [21]. In the 
subacute phase of infection, HEV RNA may already be undetectable and the antibody kinetic 
needs to be monitored in a follow-up testing. Unfortunately, a consecutive serum sample is often 
unavailable. We managed to collect paired sera from only 2.4% of tested patients. Furthermore, 
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the diagnosis of HEV infection solely by serological testing may result in false negative findings 
when HEV is recently acquired. Therefore, diagnosis in such cases needs to be assessed by 
further testing of a new serum and/or with HEV RT-PCR.  
Whether serotyping is even possible via different specific antibodies against genotype 1 
or 3 by LIA, and if these antibodies are cross protective, remains to be elucidated. The current 
data set by Pas et al [21] show cross reactivity between known genotype 1 and 3 sera. We found 
high reactivity against the N-terminal (O2N) and C-terminal parts (O2C) of the capsid protein for 
IgM and IgG, respectively, similar as the specific LIA bands findings in Germany [2, 33]. Further 
follow-up studies during HEV disease are needed to reveal the expression of different antigens in 
HEV pathways and the role of specific antibodies.  
In conclusion, our findings show a rather high HEV seroprevalence in patients with 
hepatic disorders comparing with HIV-infected patients in Croatia. Discordant findings by 
different methods (16.9% and 10.7% anti-HEV by EIA and LIA, respectively) stress the need to 
combine complementary methods and use a two-tier approach with prudent interpretation of 
reactive serological results for hepatitis E diagnosis. Combining EIA as a screening method with 
LIA or other sensitive and highly specific EIA for additional evaluation, as well as a follow-up 
anti-HEV IgG to document possible seroconversion or IgG titre rising and also HEV RT-PCR, 
could be recommended for definite diagnosis because false positive IgM and IgG findings should 
not be neglected. 
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